Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

celyad 2020

3.398 Posts
Pagina: «« 1 ... 129 130 131 132 133 ... 170 »» | Laatste | Omlaag ↓
  1. Grote Ogen 10 juli 2020 13:28
    Hmmmm dat verklaart waarom er verkocht wordt....maar goed ik wacht verder rustig af:

    ELYAD SA/ADR (NASDAQ:CYAD) Downgraded to “Sell” at Zacks Investment Research
    Posted by Joseph McCarthy on Jul 10th, 2020

    CELYAD SA/ADR logoCELYAD SA/ADR (NASDAQ:CYAD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports.

    According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “

    CYAD has been the subject of several other research reports. William Blair reiterated a “buy” rating on shares of CELYAD SA/ADR in a report on Monday, June 1st. HC Wainwright reaffirmed a “buy” rating on shares of CELYAD SA/ADR in a research note on Thursday, May 7th. Wells Fargo & Co cut their price objective on CELYAD SA/ADR from $44.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, March 26th. Finally, ValuEngine cut CELYAD SA/ADR from a “strong-buy” rating to a “buy” rating in a report on Friday, May 29th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. CELYAD SA/ADR currently has an average rating of “Buy” and a consensus price target of $23.67.


    Shares of CYAD stock opened at $10.25 on Wednesday. CELYAD SA/ADR has a 1-year low of $4.10 and a 1-year high of $14.98. The company has a 50-day moving average of $10.66 and a two-hundred day moving average of $9.68. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.07.

    Large investors have recently bought and sold shares of the business. UBS Group AG increased its position in shares of CELYAD SA/ADR by 241.2% during the fourth quarter. UBS Group AG now owns 3,064 shares of the company’s stock worth $32,000 after acquiring an additional 2,166 shares during the period. Jane Street Group LLC acquired a new position in CELYAD SA/ADR during the 4th quarter worth $117,000. Morgan Stanley grew its stake in CELYAD SA/ADR by 5.1% during the 1st quarter. Morgan Stanley now owns 39,773 shares of the company’s stock worth $296,000 after purchasing an additional 1,915 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in CELYAD SA/ADR by 4.8% during the 4th quarter. Victory Capital Management Inc. now owns 999,439 shares of the company’s stock worth $10,414,000 after purchasing an additional 45,778 shares during the period. Institutional investors and hedge funds own 7.59% of the company’s stock.

    CELYAD SA/ADR Company Profile

    Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
  2. Grote Ogen 10 juli 2020 13:29
    Sommigen blijven blijkbaar toch nog bij Buy:

    CELYAD SA/ADR (NASDAQ:CYAD) has earned a consensus rating of “Buy” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $20.00.

    CYAD has been the subject of a number of analyst reports. William Blair restated a “buy” rating on shares of CELYAD SA/ADR in a research note on Monday, June 1st. Wells Fargo & Co reduced their price objective on shares of CELYAD SA/ADR from $44.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, March 26th. ValuEngine lowered shares of CELYAD SA/ADR from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 29th. HC Wainwright reiterated a “buy” rating on shares of CELYAD SA/ADR in a research note on Thursday, May 7th. Finally, Zacks Investment Research lowered shares of CELYAD SA/ADR from a “hold” rating to a “sell” rating in a research note on Wednesday.
  3. twopence 10 juli 2020 22:27
    Over deze beoordelaar word in het algemeen geen positieve ervaringen medegedeeld. Zacks Investment Research de aandelen van CELYAD SA / ADR van een 'hold'-rating naar een' sell'-rating in een onderzoeksnota op woensdag.

  4. Noob nr1 14 juli 2020 07:54
    ABM FN) Celyad Oncology heeft goedkeuring van de Amerikaanse FDA gekregen om een Fase 1 studie met CYAD-211 uit te mogen voeren. Dit kondigde het Waalse biotechbedrijf dinsdagochtend aan.

    De shRNA-gebaseerde allogene kandidaat CYAD-211 wordt gebruikt voor de behandeling van patiënten met recidiverende / refractaire multipel myeloom.

    De Fase 1 studie zal tegen het einde van het jaar van start gaan, aldus Celyad.
  5. Lucid 14 juli 2020 09:16
    Al 5% lager sinds opening, zo kennen we Celyad weer. Spijtig dat het nieuws komt op een dag met negatief beurssentiment.
  6. [verwijderd] 14 juli 2020 10:20
    quote:

    Lucid schreef op 14 juli 2020 09:16:

    Al 5% lager sinds opening, zo kennen we Celyad weer. Spijtig dat het nieuws komt op een dag met negatief beurssentiment.
    niet te vroeg klagen ;-)
  7. Grote Ogen 14 juli 2020 11:24
    KBC Securities herhaalt het koopadvies voor Celyad koersdoel € 18
    dinsdag 14 juli 2020 - 08:43u -

    Op naar de € 18 :)
3.398 Posts
Pagina: «« 1 ... 129 130 131 132 133 ... 170 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.153
AB InBev 2 5.543
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.406
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.919
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 193
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.884
Aedifica 3 927
Aegon 3.258 323.175
AFC Ajax 538 7.092
Affimed NV 2 6.306
ageas 5.844 109.908
Agfa-Gevaert 14 2.070
Ahold 3.538 74.354
Air France - KLM 1.025 35.310
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.056
Alfen 16 25.446
Allfunds Group 4 1.522
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.182
AMG 972 134.617
AMS 3 73
Amsterdam Commodities 305 6.752
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 501
Antonov 22.632 153.605
Aperam 92 15.098
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.808
Arcelor Mittal 2.035 321.056
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.365
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 30
ASIT biotech 2 697
ASMI 4.108 39.679
ASML 1.767 111.477
ASR Nederland 21 4.521
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.260
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.456

Macro & Bedrijfsagenda

  1. 09 april

    1. Hypotheekaanvragen - wekelijks (VS)
    2. Constellation Brands cijfers vierde kwartaal (VS)
    3. Delta Air Lines cijfers eerste kwartaal (VS)
    4. Ahold Delhaize jaarvergadering
    5. SBM Offshore jaarvergadering
    6. Groothandelsvoorraden, februari (VS)
    7. Olievoorraden - wekelijks (VS)
    8. Federal Reserve, notulen (VS) volitaliteit verwacht
  2. 10 april

    1. Consumenten- en producentenprijzen, maart (Chi)
    2. Industriële productie, februari (NL)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht